Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial

Fawzi, A.M.; Kamel, Mostafa; Salem, Emad A.; Desoky, Esam; Omran, Mohamed; Elgalaly, Hazem; Sakr, Ahmed; Maarouf, Aref; Khalil, Samah R.

doi:10.1016/j.aju.2016.11.001

Cited by 19 publications

(13 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eardly et al, 23 2004 Egerdie et al, 24 2012 Evilyaoglu et al, 25 Farca et al, 26 2008 Fawzi et al, 27 Gacci et al, 28 Miner et al, 47 2008 Moncada et al, 48 2009 Moon et al, 49 2015 Nunes et al, 50 2013 Nurnberg et al, 51 2003 Orr et al, 52 2006 Ortaç et al, 53 2013 Paick et al, 54 2008 Paick et al, 55 2008 Paick et al, 56 2010 Park et al, 57 2010 Park et al, 58 2010 Park et al, 59 2015…”

Section: Discussionmentioning

confidence: 99%

Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Placebo responses in the treatment of erectile dysfunction (ED) are poorly described in the literature to date. OBJECTIVE To quantify the association of placebo with ED outcomes among men enrolled in placebo-controlled, phosphodiesterase 5 inhibitor (PDE5I) trials. DATA SOURCES For this systematic review and meta-analysis, a database search was conducted to identify double-blind, placebo-controlled studies using PDE5Is for the treatment of ED published

show abstract

Section: Discussionmentioning

confidence: 99%

Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Concurrently, there is a correlation between patients with ejaculatory disorders after the use of α-blockers, whose explanation is that blockade of α-adrenergic receptors in the urinary tract causes relaxation of the smooth muscle of the epididymis, seminal ducts, and vas deferens, which can lose the power of contraction and, therefore, of semen ejection. The ejaculatory disorder resulting from tamsulosin is characterized as retrograde ejaculation [33,[42][43][44][45][46][47][48][49][50][51].…”

Section: Discussionmentioning

confidence: 99%

The Adverse Effects of Tamsulosin in Men with Benign Prostatic Hyperplasia, a Review of the Literature

Leibacher¹,

Silva²

2019

AJLS

View full text Add to dashboard Cite

In the United States, tamsulosin is the most prescribed drug for benign prostatic hyperplasia (BPH) treatment.However, less is known about the adverse effects and mechanism of action of the drug in the organism. So, the aim of this review is to evaluate the benefits and harms of tamsulosin therapy in patients with BPH. A literature analysis was realized using the database of the National Center for Biotechnology Information (NCBI) MEDLINE®. The data collection was carried out in a retrospective of 10 years from 2008. Thus, we considered some measurements parameters used in different studies for a reliable comparison of the works. Tamsulosin has been characterized as an effective treatment for BPH. However, some studies demonstrate that the epithelial elements remain proliferative even after the administration of the drug and may be involved in the continuous growth of the gland. Also, tamsulosin can directly impact on the ejaculation process, cognitive functions and mental health of men. BPH affects approximately 50% of men between 50 and 60 years old. Beyond that, 90% of men in their eighth decade of life will present anatomical evidence of BPH. Therefore, the treatment with tamsulosin, an α1adrenergic antagonist that promotes the relaxation of the prostate smooth muscle, is essential to diminish the gland size and restore the urinary flow. However, its administration must be assessed for a better response and lower risk of adverse effects in those patients.

show abstract

“…Among the 7 studies, six trials were used to compare the relative IPSS's improving efficacy of different kinds of PDE5-Is with tamsulosin for the treatment of BPH-LUTS with or without ED [6,[9][10][11][12][13]; six trials were used to compare the relative Q max 's improving efficacy [6,[10][11][12][13][14]; four trials were used to compare the relative IIEF's improving efficacy [6,10,11,13], and six trials were used to compare the relative Table 1: 25-item CONSORT checklist. Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Total score…”

Section: Baseline Characteristics Of Includedmentioning

confidence: 99%

“…✓: fulfilled the item, ×: did not fulfill the item. BioMed Research International safety [6,[9][10][11][12][13] (Figure 1). The ranking of probability of different interventions was estimated by comparing the SUCRA shown in Table 3.…”

Section: Baseline Characteristics Of Includedmentioning

confidence: 99%

Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis

Zhang

Cai

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Purpose. The purpose of this study was to compare the relative safety and efficacy of different types of phosphodiesterase type 5 inhibitors (PDE5-Is) with tamsulosin for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostate hyperplasia (BPH) (BPH-LUTS) with or without erectile dysfunction (ED). Methods. We use the Stata version 13.0 to conduct the network meta-analysis (NMA) with a random effects model of the Bayesian framework. The International Prostate Symptom Score (IPSS), Maximum Urinary Flow Fate (Qmax), International Index of Erectile Function (IIEF), and their credible intervals (CI) were used to compare the efficacy and safety of every medical intervention, including sildenafil plus tamsulosin, tadalafil plus tamsulosin, and vardenafil plus tamsulosin. Results. Seven RCTs including 531 participants with seven interventions were analyzed. The results of NMA SUCRA showed that compared with different doses or types of PDE5-Is combined with tamsulosin (0.4 mg qd), the sildenafil (25 mg qd) combined with tamsulosin (0.4 mg qd) group had the greatest probabilities of being the best in the achievement of improving IIEF. The sildenafil (25 mg 4 days per week) combined with tamsulosin (0.4 mg qd) group had the greatest probabilities of being the best in the achievement of improving Qmax, whereas sildenafil (25 mg qd) combined with tamsulosin (0.4 mg qd) ranked the best for the safety outcomes. Conclusions. This meta-analysis indicates that sildenafil combined with tamsulosin is the best effective and tolerated treatment option for BPH-LUTS with or without ED. Further RCTs are strongly required to provide more direct evidence.

show abstract

Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial

Cited by 19 publications

References 24 publications

Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials

Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials

The Adverse Effects of Tamsulosin in Men with Benign Prostatic Hyperplasia, a Review of the Literature

Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis

Contact Info

Product

Resources

About